Novelty of explained: this guide covers what it means, who it applies to, the step-by-step process, documents required, fees, due dates and penalties in India — so you can stay compliant with confidence and avoid costly mistakes.
Paragraph 7 of the Pharmaceutical Patent Guidelines (October 2014) is the Office's working method for novelty in drug-related applications. It deals with how prior documents are read, how a generic disclosure relates to a specific one, how implicit and inherent disclosure count, and how combination and product-by-process claims are treated.
Novelty is tested document by document: separate items of prior art are not combined (7.2). A specific disclosure destroys the novelty of a generic claim; a generic disclosure does not necessarily destroy the novelty of a specific one. The Office also reads implicit and inherent disclosure (7.4, 7.5) and treats a product-by-process claim as a claim to the product, so a known product is not made new by a new process (7.9). The Guidelines are the Patent Office's guidance and do not have the force of law; the Patents Act, 1970 and the Patents Rules, 2003 as now in force prevail.
The Office revises its guidelines, so check the current version on ipindia.gov.in. This document dates from October 2014. It cites decisions of the IPAB, which has since been abolished; appeals now go to the High Court (see our post on IPAB dissolution). For the general method, see our article on the Manual's novelty chapter; and for help with a novelty objection, a patent objection reply can use the points below.
The statutory frame (paragraph 7.1)
The Guidelines recall the definition of "new invention" in section 2(1)(l) and say that prior art is construed under that clause and under section 13 read with sections 29 to 34. They refer to the Manual's novelty guidance, which they cite as paragraph 08.03.02; in the Manual of 2019 the novelty paragraph is 09.03.02, covered in the article linked above.
How prior documents are read
| Paragraph | Rule in the Guidelines | What it means in practice |
|---|---|---|
| 7.2 Documents | Separate items of prior art are generally not combined for novelty, nor are separate embodiments in one document unless the combination is suggested or essentially linked | One document, one test; combining belongs to inventive step |
| 7.2 Markush | If some compounds in a Markush formula fall within one prior art document and others within another, all documents are to be cited | Expect several citations against a broad formula |
| 7.2 Generic and specific | A generic disclosure may not take away novelty of a specific disclosure; a specific disclosure takes away the novelty of a generic one | Claim narrowly if a specific compound is in the prior art; a generic prior formula alone does not anticipate your specific compound |
| 7.3 Relevant date | A document is read as a skilled person would have read it on its date; the publication must precede the priority date; an earlier-priority Indian application published later counts as prior claiming; the document must be enabling | Check the dates and whether the citation actually teaches how to make the thing |
| 7.4 Implicit disclosure | A feature the skilled reader would read into the document counts, if the skilled person would inevitably arrive at the claimed result | An unspoken feature can still anticipate |
| 7.5 Inherent anticipation | A single prior reference anticipates if a missing characteristic is necessarily present in it | Showing the characteristic is not in the document is not enough if it follows necessarily |
The inherent anticipation paragraph relies on an IPAB ruling, Enercon (India) Limited v Aloys Wobben, as cited in the Guidelines.
The two novelty examples on generic and specific disclosure (paragraph 7.6)
Example 1 (Markush against Markush). A class of heterocyclic compounds claimed by a formula, with a prior art formula covering similar compounds, where the claimed substituents are all picked from lists in the prior art. The Office's analysis is that the examiner must check whether the compounds specifically disclosed in the prior art unambiguously take away the novelty of the compounds in question. If they do not, the generic prior disclosure may still be cited for inventive step.
Example 2 (a salt of a known compound). A fumarate salt of a known compound where the prior art specifically discloses another salt of it, mentions many pharmaceutically acceptable salts and lists fumaric acid among salt-forming acids, but never specifically discloses the fumarate. The Office's analysis is that the implicit disclosure anticipates the claim.
The two examples show the line. A long list of options in the prior art, with the specific option never singled out, is a generic disclosure; but where the skilled reader would readily arrive at the specific salt, the Office treats it as implicitly disclosed. The salt example links to section 3(d) as well; see our article on paragraph 10.
Combination and composition claims (paragraphs 7.7 and 7.8)
The Guidelines say combination claims usually escape the novelty question and are dealt with under inventive step or section 3, but where the combination is already in the public domain it should be dealt with under novelty also. They give two examples.
- A composition for corneal healing of vitamin A in a sterile buffer, where the prior art discloses eye-drops with vitamin A, a sterile buffer and other excipients for rewetting contact lenses. The claim lacks novelty because the prior art discloses all the features of the claimed composition.
- A solution with a stated concentration range of an active ingredient, where the prior art gives a broader range and states a preference for less than a value that is the upper end of the claimed range. The skilled person would inevitably read the value at the end of the range, so the claimed range is anticipated. The Office also notes that the other features claimed were not distinguishing, because the preparation methods were similar and there was no reason to expect a different result.
The practical point is that a new purpose for a known composition does not make the composition novel, and that a narrow range whose end point is in the prior art is at risk.
Product-by-process claims (paragraph 7.9)
A claim to a product defined by how it is made is a claim to the product. It is anticipated by any prior disclosure of that product, whatever its method of production. The Guidelines cite an IPAB order, The Research Foundation of State University of New York v Assistant Controller of Patents, as cited there, for the statement that such a claim must define a novel and non-obvious product and its patentability cannot depend on the process limitations alone. The applicant must therefore show that the product, though defined in process terms, is neither anticipated nor obvious from any prior product.
Paragraph 7.10 gives two examples.
- Nanoparticles loaded with a photosensitive drug. The method claims were allowable because the prior art did not teach the claimed method of synthesis; the composition claims defined by the same method were refused because the drug was the same, only the carrier differed, and the composition had known constituents with no enhanced effect shown.
- A compound obtained by a named process. The prior art teaches the same compound with the same characteristics made by another process; the claim lacks novelty.
What the examiner checks, and what to file
| Examiner's question | What the applicant should show |
|---|---|
| Does one document disclose every element of the claim, expressly or by necessary implication? | Features missing from each cited document, with evidence |
| Is a specific compound, salt or range already disclosed by name or by direct pointing? | A claim that is narrower than, or different from, the specific prior disclosure |
| For a product-by-process claim, is the product itself new? | Data that the product differs in structure or property from the known product |
| Is the cited document enabling? | Reasons why it does not give a clear direction to the claimed invention |
A worked example (invented)
Sanjeevani Pharma claims the hydrochloride salt of a known antiviral compound, where a prior patent names the compound and lists several acids, including hydrochloric acid, as possible salt formers. The examiner raises lack of novelty on the basis of paragraph 7.6, Example 2. Sanjeevani replies that the prior patent never prepares the hydrochloride and shows data that the salt has a markedly different property; it accepts that the novelty argument is weak and also prepares a section 3(d) argument. The point is that the reply addresses implicit disclosure directly, rather than arguing only that the salt is not named.
Common lapses
- Arguing that a feature is not expressly mentioned when the skilled reader would inevitably read it.
- Combining prior documents in a novelty argument.
- Drafting a product-by-process claim and relying on the novelty of the process.
- Claiming a range whose end point appears in the prior art.
Need help with a novelty objection on a pharmaceutical claim?
Novelty objections in this field turn on the exact wording of the cited document and the claim. Our team can compare them, prepare the reply and, where needed, advise on narrowing the claim. See patent objection reply, and read next about inventive step under paragraph 8.
Key takeaways
- Novelty is tested against single documents; combining is for inventive step.
- A specific disclosure destroys novelty of a generic claim, not the reverse.
- Implicit and inherent disclosure can anticipate.
- A product-by-process claim stands or falls on the product.
- The IPAB decisions are cited only as illustrations; appeals now go to the High Court.
Read next
- Pharmaceutical Patent Guidelines 2014, paragraphs 1 to 6: scope, claims and search
- Pharmaceutical Patent Guidelines 2014, paragraph 8: inventive step
- Manual Chapter 9: how novelty is assessed
- What Is Patentable in India: Novelty and Inventive Step
Disclaimer: Based on the manuals and guidelines published by the Office of the Controller General of Patents, Designs and Trade Marks that are named in the article, as consulted on 4 October 2026. They are guidance and do not have the force of law; the Patents Act, 1970 and the Patents Rules, 2003 as amended (including the 2024 amendment rules) prevail, and the current versions on ipindia.gov.in should be checked. This article is general information, not legal advice; check the official text before acting.